Developing novel therapies to address unmet medical needs associated with debilitating Women's Health conditions.



QUE Oncology is a clinical stage company developing drugs for large unmet medical needs. The company’s lead drug program,

Q-122 is focussed on the treatment of hot flashes in breast cancer patients and survivors undergoing endocrine therapy.


Several clinical studies with Q-122 have shown the drug to be safely administered to over 60 patients and healthy volunteers.

QUE Oncology has recently completed recruitment for a double blinded placebo controlled Phase 2 study in breast cancer patients and survivors.


QUE was formed in 2013 through a joint venture between Emory University in Atlanta and the University of Queensland (UQ) research commercialization company, UniQuest.


Backed by a A$21.5M capital raise (June 2017) led by Australia’s Medical Research Commercialization Fund (MRCF) and Uniseed, QUE is well funded to execute on its clinical development programs. 


QUE Oncology is a lean organisation with a core team who have extensive expertise in the drug development process. Backed by key consultants and clinicians with significant experience in pharmaceutical drug research and development, QUE leverages the best experts on a global scale.


QUE Drug Candidate

Q-122 for the treatment of hot flashes in breast cancer patients.

QUE Oncology’s lead asset is Q-122. It is currently being developed for the treatment of hot flashes in women diagnosed with breast cancer who are receiving hormonal therapy. Q-122 is an orally available small molecule that has been investigated in several in vitro and in vivo pharmacology studies. The clinical results have shown that Q-122 has an excellent safety profile and warrants the need for further clinical studies to assess the efficacy of the drug in the treatment of hot flashes. 



Cancer is a leading cause of death. In 2012, an estimated 14.1 million cancer cases occurred worldwide. By 2035, it is estimated that 24 million cancer cases will occur on an annual basis. Although advances in the management of cancer occur frequently, there are still a number of types of cancer for which there is no, or minimally, effective therapy. Also, side effects from cancer treatment often affect the utility of the treatment or the patient’s quality of life.

At QUE Oncology, research is directed towards bringing to market first-in-class drugs that address unmet medical needs.

Through research carried out at Dr Dennis Liotta’s lab, the lead inventor of Q-122, QUE is developing safe, orally available clinical agents for the control of hot flashes in breast cancer survivors undergoing endocrine therapy as well as for the broader market of post-menopausal women. Dr Liotta is well recognised as one of the worlds leading drug developers, having been one of the inventors associated with ten FDA approved therapeutics.



General inquiries:

Business Development:

Name *

Email *



Thanks! Message sent.